7154-34-9

Basic information

• Product Name: 2,4-DIAMINO-6-NITROQUINAZOLINE
• Synonyms: 6-NITROQUINAZOLINE-2,4-DIAMINE;2,4-DIAMINO-6-NITROQUINAZOLINE;Nsc73515
• CAS NO: 7154-34-9
• Molecular Formula: C₈H₇N₅O₂
• Molecular Weight: 205.17
• Mol File: 7154-34-9.mol
• Article Data: 9

Chemical Properties

• Melting Point: >360°C
• Boiling Point: 560.8 °C at 760 mmHg
• Flash Point: 293 °C
• Appearance: /
• Density: 1.623 g/cm³
• Vapor Pressure: 1.32E-12mmHg at 25°C
• Refractive Index: 1.825
• BRN: 749531
• CAS DataBase Reference: 2,4-DIAMINO-6-NITROQUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DIAMINO-6-NITROQUINAZOLINE(7154-34-9)
• EPA Substance Registry System: 2,4-DIAMINO-6-NITROQUINAZOLINE(7154-34-9)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 7154-34-9(Hazardous Substances Data)

Usage

General Description

2,4-DIAMINO-6-NITROQUINAZOLINE is a chemical compound with the molecular formula C8H6N6O2. It is a nitroquinazoline derivative with two amino groups and a nitro group. 2,4-DIAMINO-6-NITROQUINAZOLINE has been studied for its potential as an anti-cancer drug, with research indicating that it may have cytotoxic effects on cancer cells. It has also been investigated for its potential use as a precursor in the synthesis of other organic compounds. 2,4-DIAMINO-6-NITROQUINAZOLINE has been the subject of scientific research due to its interesting chemical properties and potential applications in the pharmaceutical and chemical industries.

InChI:InChI=1/C8H7N5O2/c9-7-5-3-4(13(14)15)1-2-6(5)11-8(10)12-7/h1-3H,(H4,9,10,11,12)

Upstream product

• 17420-30-3 5-nitroanthranilonitrile 
• 113-00-8 guanidine nitrate 
• 124-46-9 guanidine hydrogen carbonate 
• 593-85-1 diguanidine carbonate 
• 50-01-1 guanidine hydrochloride 
• 16588-02-6 4-chloro-3-cyanonitrobenzene 

Downstream Products

• 13953-69-0 N⁶-(4-methoxy-benzylidene)-quinazoline-2,4,6-triamine 
• 38947-89-6 N⁶-(2-nitrobenzyl)quinazoline-2,4,6-triamine 
• 13794-54-2 N⁶-(4-methylbenzyl)quinazoline-2,4,6-triamine 
• 13953-74-7 3-(((2,4-diaminoquinazolin-6-yl)amino)methyl)phenol 

Relevant articles and documents

PHOTORESPONSIVE COMPOUND

PROBLEM TO BE SOLVED: To provide a novel photoresponsive compound that is useful as a medicament, or a reagent for analyzing in vivo intermolecular interaction, or the like. SOLUTION: Provided is a compound represented by the following formula (I-1) or (I

Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely

Malaria parasites are a leading cause of worldwide mortality from infectious disease. Cysteine protease falcipain-2 (FP-2) and Plasmodium falciparum dihydrofolate reductase (PfDHFR) play vital roles, which are absolutely essential, in the parasite life cycle. In this study, based on the structures of uniform fragments of reported PfDHFR inhibitors and the first-generation dual inhibitors against FP-2 and PfDHFR, we identified a novel series of dual inhibitors through fragments assembly. Lead optimization led to the discovery of 24, which showed high potency against FP-2 (IC50 = 10.0 μM), PfDHFR (IC50 = 84.1 nM), P. falciparum 3D7 (IC50 = 53.1 nM), clinical isolated strains Fab9 (IC50 = 14.2 nM) and GB4 (IC50 = 23.4 nM). The in vivo inhibition assays against P. berghei in 10 days indicated 24 had a more beneficial effect on the growth inhibition of P. berghei than artemisinin and an identical effect with pyrimethamine. Additionally, 24 moderately inhibited the proliferation of chloroquine-resistant P. falciparum Dd2 strain. Collectively, these data revealed that 24 could be an excellent lead compound as FP-2 and PfDHFR dual inhibitor for the treatment of malaria.

Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents

In this paper, the design, synthesis and biological evaluation of a set of quinazoline-2,4,6-triamine derivatives (1-9) as trypanocidal, antileishmanial and antiplasmodial agents are explained. The compounds were rationalized basing on docking studies of the dihydrofolate reductase (DHFR from Trypanosoma cruzi, Leishmania major and Plasmodium vivax) and pteridin reductase (PTR from T. cruzi and L. major) structures. All compounds were in vitro screened against both bloodstream trypomastigotes of T. cruzi (NINOA and INC-5 strains) and promatigotes of Leishmania mexicana (MHOM/BZ/61/M379 strain), and also for cytotoxicity using Vero cell line. Against T. cruzi, three compounds (5, 6 and 8) were the most effective showing a better activity profile than nifurtimox and benznidazole (reference drugs). Against L. mexicana, four compounds (5, 6, 8, and 9) exhibited the highest activity, even than glucantime (reference drug). In the cytotoxicity assay, protozoa were more susceptible than Vero cells. In vivo Plasmodium berghei assay (ANKA strain), the compounds 1, 5, 6 and 8 showed a more comparable activity than chloroquine and pyrimethamine (reference drugs) when they were administrated by the oral route. The antiprotozoal activity of these substances, endowed with redox properties, represented a good starting point for a medicinal chemistry program aiming for chemotherapy of Chagas' disease, leishmaniosis and malaria.